| Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo S Hoffmeyer, O Burk, O Von Richter, HP Arnold, J Brockmöller, A Johne, ... Proceedings of the National Academy of Sciences 97 (7), 3473-3478, 2000 | 3394 | 2000 |
| Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. C Sachse, J Brockmöller, S Bauer, I Roots American journal of human genetics 60 (2), 284, 1997 | 1367 | 1997 |
| Low intensity transcranial electric stimulation: safety, ethical, legal regulatory and application guidelines A Antal, I Alekseichuk, M Bikson, J Brockmöller, AR Brunoni, R Chen, ... Clinical neurophysiology 128 (9), 1774-1809, 2017 | 1190 | 2017 |
| Metabolic gene polymorphism frequencies in control populations Cancer Epidemiology, Biomarkers & Prevention 10 (12), 1239-1248, 2001 | 1146 | 2001 |
| Functional significance of a C→ A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine C Sachse, J Brockmöller, S Bauer, I Roots British journal of clinical pharmacology 47 (4), 445-449, 1999 | 970 | 1999 |
| Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response J Kirchheiner, K Nickchen, M Bauer, ML Wong, J Licinio, I Roots, ... Molecular psychiatry 9 (5), 442-473, 2004 | 961 | 2004 |
| Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines S Rossi, A Antal, S Bestmann, M Bikson, C Brewer, J Brockmöller, ... Clinical Neurophysiology 132 (1), 269-306, 2021 | 933 | 2021 |
| The genetic determinants of the CYP3A5 polymorphism E Hustert, M Haberl, O Burk, R Wolbold, YQ He, K Klein, AC Nuessler, ... Pharmacogenetics and Genomics 11 (9), 773-779, 2001 | 853 | 2001 |
| Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) A Johne, J Brockmöller, S Bauer, A Maurer, M Langheinrich, I Roots Clinical Pharmacology & Therapeutics 66 (4), 338-345, 1999 | 819 | 1999 |
| Clinical consequences of cytochrome P450 2C9 polymorphisms J Kirchheiner, J Brockmöller Clinical Pharmacology & Therapeutics 77 (1), 1-16, 2005 | 652 | 2005 |
| Nomenclature for human CYP2D6 alleles AK Daly, J Brockmoller, F Broly, M Eichelbaum, WE Evans, FJ Gonzalez, ... Pharmacogenetics and Genomics 6 (3), 193-201, 1996 | 610 | 1996 |
| NAD (P) H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity L Wojnowski, B Kulle, M Schirmer, G Schlüter, A Schmidt, ... Circulation 112 (24), 3754-3762, 2005 | 592 | 2005 |
| CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants: a first step towards subpopulation‐specific dosages J Kirchheiner, K Brøsen, ML Dahl, LF Gram, S Kasper, I Roots, F Sjöqvist, ... Acta Psychiatrica Scandinavica 104 (3), 173-192, 2001 | 573 | 2001 |
| Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication J Kirchheiner, H Schmidt, M Tzvetkov, J Keulen, J Lötsch, I Roots, ... The pharmacogenomics journal 7 (4), 257-265, 2007 | 557 | 2007 |
| Combined Analysis of Inherited Polymorphisms in Arylamine N-Acetyltransferase 2, Glutathione S-Transferases M1 and T1, Microsomal Epoxide Hydrolase, and … J Brockmöller, I Cascorbi, R Kerb, I Roots Cancer Research 56 (17), 3915-3925, 1996 | 478 | 1996 |
| A C4887A Polymorphism in Exon 7 of Human CYP1A1: Population Frequency, Mutation Linkages, and Impact on Lung Cancer Susceptibility I Cascorbi, J Brockmöller, I Roots Cancer research 56 (21), 4965-4969, 1996 | 457 | 1996 |
| Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population EA Gaikovitch, I Cascorbi, PM Mrozikiewicz, J Brockmöller, R Frötschl, ... European journal of clinical pharmacology 59, 303-312, 2003 | 450 | 2003 |
| Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. I Cascorbi, N Drakoulis, J Brockmöller, A Maurer, K Sperling, I Roots American journal of human genetics 57 (3), 581, 1995 | 431 | 1995 |
| Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene A Johne, K Köpke, T Gerloff, I Mai, S Rietbrock, C Meisel, S Hoffmeyer, ... Clinical Pharmacology & Therapeutics 72 (5), 584-594, 2002 | 419 | 2002 |
| Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA I Koch, R Weil, R Wolbold, J Brockmöller, E Hustert, O Burk, A Nuessler, ... Drug Metabolism and Disposition 30 (10), 1108-1114, 2002 | 419 | 2002 |
